When a medical product innovator has reached the point at which preclinical work is necessary to achieve the next milestone, they have already surmounted significant obstacles. They are nearer to realizing the possibility that their product will enter the market and patient care than ever before.
While this may be true, preclinical work, especially GLP studies, are costly and critical to the product’s successful regulatory submission. Efficiency and quality in preclinical work begins with a robust preclinical study protocol. Preclinical protocols are the foundation on which reports required by regulatory bodies are built.
What elements in a preclinical study protocol give the study the best opportunity for clarity in a final report that will ultimately be reviewed by regulators? Join GCMI’s Irena Brants and Deepal Panchal for this 30 minute webinar on May 14 at 11:00 a.m. to find out.